Does Rallies show Form 4 insider transactions for QDEL?

Yes. Rallies tracks QDEL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is QDEL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for QDEL. It does not provide personalized investment advice.

QDEL (QuidelOrtho Corporation Common Stock) Stock Analysis - Insider Trades

QuidelOrtho Corporation Common Stock (QDEL) is a publicly traded Healthcare sector company. As of May 21, 2026, QDEL trades at $11.95 with a market cap of $739.19M and a P/E ratio of -0.67. QDEL moved +4.48% today. Year to date, QDEL is -60.38%; over the trailing twelve months it is -63.22%. Its 52-week range spans $9.92 to $49.45. Analyst consensus is neutral with an average price target of $12.03. Rallies surfaces QDEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading QDEL stock inside the company?

Recent QDEL insider activity includes Busky Joseph M. bought 3.37K, Strobeck Matthew bought 10.00K, Busky Joseph M. bought 3.37K, Blaser Brian J. bought 10.54K, and RHOADS ANN D bought 750. Rallies tracks insider transaction dates, shares, prices, and estimated values.

QDEL Key Metrics

Key financial metrics for QDEL
Metric	Value
Price	$11.95
Market Cap	$739.19M
P/E Ratio	-0.67
EPS	$-17.80
Dividend Yield	0.00%
52-Week High	$49.45
52-Week Low	$9.92
Volume	316
Avg Volume	0
Revenue (TTM)	$2.66B
Net Income	$-1.21B
Gross Margin	0.00%

Recent QDEL Insider Trades

Busky Joseph M. bought 3.37K (~$79.74K) on Feb 13, 2026.
Strobeck Matthew bought 10.00K (~$239.59K) on Feb 13, 2026.
Busky Joseph M. bought 3.37K (~$79.74K) on Feb 13, 2026.
Blaser Brian J. bought 10.54K (~$248.66K) on Feb 13, 2026.
RHOADS ANN D bought 750 (~$21.21K) on Dec 10, 2025.

Latest QDEL News

QuidelOrtho Q1 revenue $620M, POC sales down 34% as guidance trimmed — May 5, 2026
QuidelOrtho Podcast Reveals 4,000 Congenital Syphilis Cases Despite Early-Stage Declines — Apr 23, 2026
QuidelOrtho Names Sisitsky Chief Legal Officer Effective March 23 — Mar 24, 2026
QuidelOrtho Launches High-Sensitivity Troponin for 0/1-Hour Cardiac Rule-Out Protocols — Feb 19, 2026
QuidelOrtho Signs Lifotronic Deal to Add 25 Assays Across 70+ Platforms — Feb 17, 2026

QDEL Analyst Consensus

6 analysts cover QDEL: 0 strong buy, 1 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $12.03.

Common questions about QDEL

Who is trading QDEL stock inside the company?: Recent QDEL insider activity includes Busky Joseph M. bought 3.37K, Strobeck Matthew bought 10.00K, Busky Joseph M. bought 3.37K, Blaser Brian J. bought 10.54K, and RHOADS ANN D bought 750. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for QDEL?: Yes. Rallies tracks QDEL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is QDEL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for QDEL. It does not provide personalized investment advice.